At the recent annual meeting of the Muscular Dystrophy Association, Peter Marks, head of the Center for Biologics Evaluation and Research, noted the importance of using the accelerated approval channel for gene therapies: "We can’t be so careful about our approvals under accelerated approval that we prevent potentially lifesaving therapies from getting to market in a timely manner," he said.
read full article ›WOoT! We are very happy to have you on board Denise Wolff!
read full article ›